QUOTE AND NEWS
SeekingAlpha  Aug 11  Comment 
ByScrying Biotech: I don't always like the decisions my editors at Seeking Alpha make. And I'm sure they don't care. John Thero doesn't like the decision to postpone ANCHOR approval that the FDA made. And I'm sure they don't care. Because FDA...
SeekingAlpha  Aug 10  Comment 
ByIAEResearch: Amarin (NASDAQ:AMRN) reported second quarter results on August 7, 2014 and the company has made considerable progress in a number of areas. The company reported basic EPS of $0.09 and diluted EPS of $0.08. However, for the six-month...
SeekingAlpha  Aug 9  Comment 
Amarin Corporation PLC (AMR) Q2 2014 Earnings Conference Call August 07, 2014 04:30 a.m. ET Executives Michael James Farrell – Principal Financial Officer, Principal Accounting Officer and Controller John F. Thero – Chief...
SeekingAlpha  Aug 4  Comment 
ByElephant Analytics: Vascepa's prescription numbers have recently improved after a lengthy period of very slow growth. It appears that Amarin's (NASDAQ:AMRN) co-promotion agreement with Kowa is starting to show some dividends. However, this...
Benzinga  Jul 31  Comment 
Amarin (NASDAQ: AMRN) moved higher Thursday following upbeat biotech commentary from TheStreet.com's Adam Feuerstein. Feuerstein mentioned that Amarin, “is expected to hear soon on an appeal to a top official at the FDA requesting a reversal...
TheStreet.com  Jul 31  Comment 
BOSTON (TheStreet) -- It might be time to get bullish on Amarin .You're not hallucinating. This longtime Amarin bear believes there's now a compelling argument for going long the stock or its options -- if only for a speculative trade. The idea of...
SeekingAlpha  Jul 21  Comment 
ByScrying Biotech: Amarin (NASDAQ:AMRN) president and chief executive officer, John Thero has a performance history predicated on poor decision-making. He's been instrumental in bringing the company and perhaps the most important drug ever...
SeekingAlpha  Jun 27  Comment 
ByQuoth the Raven: I don't really want to harangue Amarin (AMRN) too much. The company and its shareholders have gone through enough since the company's FDA approval of Vascepa years ago. The company, after failing in its appeal for approval of...
SeekingAlpha  Jun 12  Comment 
By Big Alpha Research: In my previous article, I wrote about the risks and returns associated with investing in Amarin Corp. (AMRN), and concluded that the company should have enough cash to fund its operations and the research and development...
SeekingAlpha  Jun 12  Comment 
Amarin Corporation PLC (AMRN) Goldman Sachs 2014 Global Healthcare Conference June 11, 2014 6:20 p.m. ET Executives Gary Nachman – Goldman Sachs John Thero – Amarin Corporation PLC President and CEO Analysts ...





 



References

This is a test No its not

Wikinvest © 2006, 2007, 2008, 2009, 2010, 2011, 2012. Use of this site is subject to express Terms of Service, Privacy Policy, and Disclaimer. By continuing past this page, you agree to abide by these terms. Any information provided by Wikinvest, including but not limited to company data, competitors, business analysis, market share, sales revenues and other operating metrics, earnings call analysis, conference call transcripts, industry information, or price targets should not be construed as research, trading tips or recommendations, or investment advice and is provided with no warrants as to its accuracy. Stock market data, including US and International equity symbols, stock quotes, share prices, earnings ratios, and other fundamental data is provided by data partners. Stock market quotes delayed at least 15 minutes for NASDAQ, 20 mins for NYSE and AMEX. Market data by Xignite. See data providers for more details. Company names, products, services and branding cited herein may be trademarks or registered trademarks of their respective owners. The use of trademarks or service marks of another is not a representation that the other is affiliated with, sponsors, is sponsored by, endorses, or is endorsed by Wikinvest.
Powered by MediaWiki